Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus

• Main Authors: Cheng-Yi Wang (Author), Kuang-Ming Liao (Author), Ya-Hui Wang (Author), Kuang-Hung Chen (Author), Shulin Chuang (Author), Chia-Jung Liu (Author), Chin-Chung Shu (Author), Hao-Chien Wang (Author)
• Format: Book
• Published: Elsevier, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Type 2 diabetes mellitus (DM) is a risk factor for mycobacterial pulmonary infections (MPI), including tuberculosis (TB) and nontuberculous mycobacterial lung disease (NTM-LD). Dipeptidyl peptidase IV inhibitor (DPP4i), a common DM medication, has an immune-modulation effect that raises...